uniQure N.V. (NASDAQ:QURE) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operation and Financial
Condition

On May9, 2017, uniQure N.V. (the Company) issued a press release
announcing its financial results for the quarter ended March31,
2017 and highlighting company progress. A copy of the press
release is furnished as Exhibit99.1 to this Current Report on
Form8-K.

The information furnished to this Item 2.02, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934 (the Exchange Act) or
otherwise subject to the liabilities under that Sectionand shall
not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act,
except as shall be expressly set forth by specific reference in
such filing.

Item 9.01 Financial Statements and
Exhibits

(d) Exhibits

About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company’s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

uniQure N.V. (NASDAQ:QURE) Recent Trading Information

uniQure N.V. (NASDAQ:QURE) closed its last trading session 00.00 at 4.83 with 81,334 shares trading hands.